Mile High Peptides

Home
United States
Centennial, CO
Mile High Peptides

Call Website Contact the practice

Contact information, map and directions, contact form, opening hours, services, ratings, photos, videos and announcements from Mile High Peptides, Health & Wellness Website, Havana Street, Centennial, CO.

09/07/2026

WHAT STARTS THE GROWTH HORMONE SIGNAL? Brain → Pituitary → Growth Hormone → IGF-1

🧬 What tells the body to release growth hormone?

Growth hormone is part of a communication system connecting the brain, pituitary gland and other tissues.
Here is the simple version:

🧠 The brain sends a message called GHRH.
🔬 The pituitary gland receives that message and releases growth hormone.
🧬 Growth hormone then sends signals to different tissues.
⚙️ Some of those signals lead to the production of IGF-1, which works farther down the pathway.

Growth hormone-related research compounds do not all work at the same point in this system.

Some are studied for copying the original GHRH message. Others activate the ghrelin receptor, which provides another signal connected with growth hormone release. IGF-1 LR3 is studied farther down the pathway.

Understanding where a compound fits helps researchers choose the material that matches their research question.
Different compound. Different signal. Different research question.

🔬 Part 1 of MHP Growth Hormone Signaling Research Week

Tomorrow: Sermorelin and the message that begins the pathway.

Explore the research education hub: www.milehighpeptides.com/education-hub

For laboratory research and educational purposes only. Not for human or veterinary use.

09/05/2026

🧠 Plot Twist: This One Isn’t a GLP-1 Agonist.
For the final day of MHP Metabolic Research Week, we’re stepping outside the GLP-1 pathway.
🔬 Tesofensine is fundamentally different from the GLP-1, GIP and glucagon receptor agonists we’ve explored this week.
Rather than acting as a GLP-1 receptor agonist, Tesofensine has been investigated for its effects on monoamine reuptake, involving signaling systems that include dopamine, norepinephrine and serotonin.
That gives researchers a very different mechanism to investigate.
🧬 GLP-focused research → receptor signaling
🧠 Tesofensine research → monoamine signaling
And that’s an important reminder: compounds discussed within the same broad area of metabolic research don’t necessarily work through the same biological pathway.
Different pathway. Different mechanism. Different research question.
🔬 Day 7 of 7 | MHP Metabolic Research Week
Missed one of this week’s topics? We explored GLP-1 vs. GIP vs. glucagon, Tirzepatide, Retatrutide, Survodutide, Mazdutide, Orforglipron and Tesofensine.
📚 The series may be ending, but the research doesn’t.
www.milehighpeptides.com/education-hub
For laboratory research purposes only. Not intended to diagnose, treat, cure, or prevent any disease.

09/04/2026

🔬 Does a GLP-1 Receptor Agonist Have to Be a Peptide?
No—and that’s what makes today’s research topic so interesting.
Throughout MHP Metabolic Research Week, we’ve explored several investigational compounds involving GLP-1 receptor signaling.
But Orforglipron is different.
🧬 Orforglipron is being investigated as a non-peptide, small-molecule GLP-1 receptor agonist.
That distinction gives researchers another approach for studying the same receptor family.
Think about the research question this way:
Peptide-based approach → GLP-1 receptor Small-molecule approach → GLP-1 receptor
🔬 Same receptor family. Different molecular approach.
Understanding that distinction is important because modern GLP-1 research isn’t limited to studying one type of molecular structure.
🧬 Day 6 of MHP Metabolic Research Week
Tomorrow we’re stepping outside the GLP pathway entirely with Tesofensine—and explaining why it still appears in metabolic research discussions.
📚 Curious about the science behind today’s emerging research compounds?
www.milehighpeptides.com/education-hub
For laboratory research purposes only. Not intended to diagnose, treat, cure, or prevent any disease.

09/03/2026

🧬 Same Receptor Targets. Same Research Compound? Not Necessarily.
Yesterday we explored Survodutide, an investigational compound studied for dual GLP-1 + glucagon receptor agonism.
Today we’re looking at Mazdutide—another investigational compound involving those same two receptor families.
So why study both?
🔬 Sharing receptor targets doesn’t make two research compounds identical.
Researchers can investigate differences in areas such as molecular design, receptor activity and broader pharmacologic characteristics—even when compounds are designed around similar signaling pathways.
That distinction is important when looking at emerging multi-receptor research:
Survodutide → GLP-1 + Glucagon Mazdutide → GLP-1 + Glucagon
Similar targets. Different investigational compounds.
And that’s where the research question becomes more interesting than simply counting receptors.
🧬 Day 5 of MHP Metabolic Research Week
Tomorrow we’re changing direction: Orforglipron. Does a GLP-1 receptor agonist even have to be a peptide?
📚 Compare the pathways and explore the research:
www.milehighpeptides.com/education-hub
For laboratory research purposes only. Not intended to diagnose, treat, cure, or prevent any disease.

09/02/2026

🧬 GLP-1 + Glucagon: Why Are Researchers Studying These Two Pathways Together?

We’ve gone from one receptor… to two… to three.

Now let’s look at a different combination.
🔬 Survodutide is an investigational dual receptor agonist being studied for activity at both the GLP-1 and glucagon receptors.
What makes that interesting?

GLP-1 and glucagon participate in different aspects of metabolic signaling, so researchers are investigating what happens when these two receptor pathways are targeted together within a single compound.

And here’s an important distinction from Monday:
Tirzepatide: GIP + GLP-1 Survodutide: Glucagon + GLP-1
Both involve two receptor targets—but they’re not studying the same combination of pathways.

That difference is exactly what makes modern multi-receptor research so interesting.

🔬 Different combination. Different research question.

🧬 Day 4 of MHP Metabolic Research Week

Tomorrow: Mazdutide — another GLP-1 + glucagon research compound. So what makes studying multiple compounds targeting similar pathways valuable?

📚 Continue exploring the science:
www.milehighpeptides.com/education-hub
Educational content for research purposes only. Not intended to diagnose, treat, cure, or prevent any disease.

09/01/2026

🔬 What Happens When Two Pathways Become Three?

Yesterday we explored dual-receptor research. Today, we’re adding a third pathway.

🧬 Retatrutide is an investigational triple receptor agonist designed to activate:
GLP-1 + GIP + Glucagon
Why is that scientifically interesting?

Instead of investigating one metabolic signaling pathway—or even two—researchers can examine what happens when three distinct receptor systems are engaged within the same investigational approach.

That makes Retatrutide an important subject in the evolving study of multi-receptor metabolic signaling and raises a bigger research question:

🔬 How does triple-receptor signaling differ from single- and dual-receptor approaches?

Three pathways. One fascinating research question.

🧬 Day 3 of MHP Metabolic Research Week
Tomorrow: Survodutide — why are researchers investigating GLP-1 + glucagon together?

📚 Explore the science and continue your research:
www.milehighpeptides.com/education-hub

Educational content for research purposes only. Not intended to diagnose, treat, cure, or prevent any disease.

08/31/2026

🔬 Why Target Two Receptors Instead of One?

Yesterday we looked at GLP-1, GIP and glucagon individually. Today, we’re looking at what happens when research brings two pathways together.

🧬 Tirzepatide is a dual GIP + GLP-1 receptor agonist that has become an important subject in metabolic research.
Rather than focusing exclusively on GLP-1 receptor signaling, tirzepatide provides researchers with a model for investigating how simultaneous GIP and GLP-1 receptor activity may influence interconnected metabolic pathways.
That’s what makes dual-receptor research so interesting: it’s not simply about adding another target—it’s about understanding how the signaling pathways interact.

Two receptors. One compound. A different research question.

🔬 Day 2 of MHP Metabolic Research Week

Tomorrow: Retatrutide — what changes when research moves from TWO receptor targets to THREE?

📚 Continue exploring the science at:
www.milehighpeptides.com/education-hub
Educational content for research purposes only. Not intended to diagnose, treat, cure, or prevent any disease.

08/30/2026

🔬 GLP-1 vs. GIP vs. Glucagon: Three Pathways. Different Roles.

You’ve probably heard GLP-1 mentioned—but what about GIP and glucagon?

These three signaling pathways play distinctly different roles in metabolic research, which is why scientists are increasingly interested in what happens when compounds target one, two, or even all three receptors.

🧬 GLP-1 — studied for its role in glucose-dependent insulin signaling, gastric emptying and satiety signaling.

🔬 GIP — another incretin pathway involved in glucose-dependent insulin signaling and broader metabolic processes.

⚗️ Glucagon — plays an important role in hepatic glucose regulation and energy mobilization.

Understanding these pathways provides the foundation for understanding why compounds such as tirzepatide, retatrutide, survodutide and mazdutide are generating so much research interest.

This is Day 1 of MHP Metabolic Research Week. Tomorrow, we take a closer look at Tirzepatide and dual GIP/GLP-1 receptor research.

📚 Want to go deeper into the science? Explore research articles, compound information and educational resources at:
www.milehighpeptides.com/education-hub

For laboratory research purposes only. Not intended to diagnose, treat, cure, or prevent any disease.

08/29/2026

🔬 ARA-290: A Research Spotlight on Cellular Repair Signaling

ARA-290—also studied under the name cibinetide—is a peptide-derived compound attracting scientific interest for its interaction with the Innate Repair Receptor.

Preclinical and clinical research has explored how this signaling pathway may influence inflammatory responses, cellular protection, and tissue-repair processes without stimulating red-blood-cell production. Research remains ongoing, making ARA-290 an intriguing subject for laboratories studying cellular stress and repair signaling.
Want to take a closer look at this emerging research compound?
Explore ARA-290 and visit our Education Hub at www.milehighpeptides.com/education-hub.
For laboratory research purposes only. Not intended to diagnose, treat, cure, or prevent any disease.

08/28/2026

SERMORELIN: A RESEARCH SPOTLIGHT 🔬
What makes Sermorelin relevant to peptide research?
Sermorelin is a synthetic peptide analog corresponding to the first 29 amino acids of naturally occurring growth hormone–releasing hormone, commonly known as GHRH.
In controlled laboratory settings, researchers investigate Sermorelin’s interaction with GHRH receptors, peptide signaling pathways, pituitary response mechanisms and endocrine research models.
Its defined amino-acid sequence makes it an important compound for researchers exploring receptor-mediated signaling and biological feedback mechanisms.
Explore Sermorelin product information and available research documentation from Mile High Peptides LLC.
VISIT: www.milehighpeptides.com
For research use only. Not for human or veterinary use. This content is provided for educational purposes only.

Address

Havana Street
Centennial, CO
80112

Telephone

+19704807609

Website

http://www.milehighpeptides.com/

Alerts

Be the first to know and let us send you an email when Mile High Peptides posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Practice

Send a message to Mile High Peptides:

Want your practice to be the top-listed clinic in Centennial?